Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

0
Player Avatar meeks85 (< 20) Submitted: 2/24/2013 1:43:23 PM : Outperform Start Price: $2.00 DVAX Score: -33.29

FDA Approval>Sales of Product>Learned from mistakes

Featured Broker Partners


Advertisement